Bcl-2 Antikörper (N-Term)

Produktnummer ABIN374455

Dieser Ziege Polyklonal Antikörper detektiert spezifisch Bcl-2 in WB und EIA. Es zeigt Reaktivität gegenüber Proben von Human, Maus, Ratte und Hund.

Kurzübersicht für Bcl-2 Antikörper (N-Term) (ABIN374455)

Target: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Reaktivität: Human, Maus, Ratte, Hund

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser Bcl-2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Produktdetails anti-Bcl-2 Antikörper

Bindungsspezifität: N-Term

Sequenz: AGRTGYDNRE IVMKYC

Spezifität: This antibody is expected to recognise both reported isoforms (NP_000624, NP_000648) of BCL2.

Kreuzreaktivität (Details): Species reactivity (expected):Mouse, Rat, Canine.
Species reactivity (tested):Human.

Aufreinigung: Ammonium Sulphate Precipitation followed by Antigen Affinity Chromatography using the immunizing peptide.

Immunogen: Peptide with sequence from the N Terminus of the protein sequence according to NP_000624.2, NP_000648.2. Genename: BCL2

Anwendungsinformationen

Applikationshinweise: Peptide ELISA: 1/32000. Western blot: 1 - 3 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Tris saline, pH 7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu Bcl-2

Target: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Andere Bezeichnung: Bcl-2

Hintergrund: BCL2 is an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants (alpha and beta) produced by alternate splicing, differ in their C-terminal ends. BCL2 suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. It regulates cell death by controlling the mitochondrial membrane permeability. It appears to function in a feedback loop system with caspases. BCL2 inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF1). It can form homodimers, and heterodimers with BAX, BAD, BAK and BclX(L). Heterodimerization with BAX requires intact BH1 and BH2 domains, and is necessary for anti-apoptotic activity. Also interacts with APAF1, RAF1, TP53BP2, BBC3, BCL2L1 and BNIPL.Synonyms: Apoptosis regulator Bcl-2, B-Cell CLL/lymphoma 2, BCL2, Bcl-2 alpha

Gen-ID: 596, 9606

UniProt: P10415

Pathways: MAPK Signalweg, PI3K-Akt Signalweg, Apoptose, Caspase Kaskade in der Apoptose, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Skeletal Muscle Fiber Development, Autophagie, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling